XML 199 R173.htm IDEA: XBRL DOCUMENT v3.23.4
STOCK-BASED COMPENSATION - Vallon - Q1 - Activity of Stock Options (Details) - $ / shares
3 Months Ended 9 Months Ended 12 Months Ended
Mar. 31, 2023
Sep. 30, 2023
Dec. 31, 2022
Number of options      
Outstanding, Beginning balance (in shares) 112,612 112,612  
Granted (in shares)   221,265  
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period   0  
Forfeited (in shares)   (15,863)  
Outstanding, Ending balance (in shares)   318,014 112,612
Exercisable, Ending Balance (in shares)   318,014  
Weighted average exercise price      
Outstanding, Beginning balance (in usd per share) $ 39.77 $ 39.77  
Granted (in usd per share)   2.38  
Exercised (in usd per share)   0  
Forfeited/Cancelled (in usd per share)   128.13  
Outstanding, Ending balance (in usd per share)   9.35 $ 39.77
Exercisable, Ending balance (in usd per share)   $ 9.35  
Weighted average remaining contractual term (years)      
Outstanding (years)   7 years 11 months 1 day 4 years 8 months 15 days
Exercisable (years)   7 years 11 months 1 day  
GRI Bio, Inc. (Formerly Vallon Pharmaceuticals, Inc.)      
Number of options      
Outstanding, Beginning balance (in shares) 23,142 23,142  
Granted (in shares) 0    
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period 0    
Forfeited (in shares) 0    
Outstanding, Ending balance (in shares) 23,142   23,142
Exercisable, Ending Balance (in shares) 13,112    
Weighted average exercise price      
Outstanding, Beginning balance (in usd per share) $ 118.05 $ 118.05  
Granted (in usd per share) 0    
Exercised (in usd per share) 0    
Forfeited/Cancelled (in usd per share) 0    
Outstanding, Ending balance (in usd per share) 118.05   $ 118.05
Exercisable, Ending balance (in usd per share) $ 106.79    
Weighted average remaining contractual term (years)      
Outstanding (years) 7 years 9 months 18 days   8 years 18 days
Exercisable (years) 7 years 6 months 10 days